Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app help young people with psychosis cut back on cannabis?

NCT ID NCT05310981

Symptom relief Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested a mobile app called iCanChange in 100 young adults (ages 18-35) with psychosis and cannabis use disorder. The app uses motivational interviewing and cognitive behavioral therapy techniques through short interactive modules. The main goal was to see if the app is acceptable and feasible to use, not whether it actually reduces cannabis use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
iCanChange mobile app (behavioral intervention using motivational interviewing and cognitive behavioral therapy)
What this could lead to
If successful, this could point toward a practical, app-based tool to help young people with psychosis cut down on cannabis use.
What could go wrong
This is a small pilot study (100 participants) focused on feasibility, not effectiveness. The app may not lead to lasting changes in cannabis use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Jul 2022

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants must meet all of the following criteria: 1. Young adults age 18 to 35 years old 2. Diagnosed with any psychotic disorder, which can include schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, delusional disorder, psychotic disorder not otherwise specified, brief psychotic disorder and substance-induced psychotic disorder. 3. Has been followed at an early psychosis clinic for a minimum of 3 months 4. Diagnosed with a current CUD (any severity), based on Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria 5. Currently using cannabis (used cannabis at least once in the past month) 6. Accepting an intervention for CUD to cease or decrease his/her use 7. Able to provide full informed consent 8. Available for the whole duration of the study/able to comply with study procedures 9. Able to comprehend French or English Exclusion Criteria: 1. Any medical condition that in the opinion of the psychiatrist precludes safe participation in the study or the ability to provide fully informed consent 2. Any disabling, unstable or acute mental condition that in the opinion of the psychiatrist precludes safe participation in the study or the ability to provide fully informed consent 3. Any legal/judicial status/issue, pending legal action, or other reasons in the opinion of the study team that might prevent completion of the study 4. Presence of an additional substance use disorder that, in the opinion of the psychiatrist, precludes safe participation in the study (e.g., very unstable or severe substance use disorder) 5. Currently participating in another specific cannabis use-focused intervention (other than those which are part of the intervention and control arms)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cannabis dependence psychotic disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cannabis use disorder

Contacts and locations

Locations

  • Clinic Connec-T - Institut universitaire en santé mentale de Montréal

    Montreal, Quebec, H1N3M5, Canada

  • Clinic Notre-Dame des Victoires - Centre de Recherche CERVO

    Québec, Quebec, G1J2G3, Canada

  • Clinique JAP, Centre hospitalier de l'Université de Montréal

    Montreal, Quebec, H2X 3E4, Canada

  • Foothills Medical Centre Early Psychosis Intervention Program

    Calgary, Alberta, T2N2T9, Canada

  • Nova Scotia Early Psychosis Program

    Halifax, Nova Scotia, B3H2E2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.